|
| 36255393 | Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer. | Clin Cancer Res | 2023 |
| 37524096 | Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial. | Lancet | 2023 |
| 37733980 | Pretest Video Education Versus Genetic Counseling for Patients With Prostate Cancer: ProGen, A Multisite Randomized Controlled Trial. | JCO Oncol Pract | 2023 |
| 37126020 | Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes. | Clin Cancer Res | 2023 |
| 37153742 | Selective ablation of TRA-1-60<sup>+</sup> pluripotent stem cells suppresses tumor growth of prostate cancer. | Theranostics | 2023 |
| 37211866 | <sup>18</sup> F-sodium fluoride positron emission tomography quantitation of bone metastases in African American and non-African American men with metastatic prostate cancer. | Prostate | 2023 |
| 37449003 | The impact of high intensity interval training in a diverse group of cancer survivors: CAPABLE, a pilot study. | Prev Med Rep | 2023 |
| 36540051 | Addressing multilevel barriers to clinical trial participation among Black and White men with prostate cancer through the PACCT study. | Cancer Med | 2023 |
| 36367998 | Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial. | J Clin Oncol | 2023 |
| 34363009 | PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. | Prostate Cancer Prostatic Dis | 2022 |
| 35662501 | Identification of potential biomarkers and novel therapeutic targets through genomic analysis of small cell bladder carcinoma and associated clinical outcomes. | Urol Oncol | 2022 |
| 36583025 | Biomarker-driven drug repurposing on biologically similar cancers with DNA-repair deficiencies. | Front Genet | 2022 |
| 36036607 | Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on Race. | Oncologist | 2022 |
| 35864053 | Treatment Intensification Patterns and Utilization in Patients with Metastatic Castration-Sensitive Prostate Cancer. | Clin Genitourin Cancer | 2022 |
| 36085183 | Physicians' use of plain language during discussions of prostate cancer clinical trials with patients. | Patient Educ Couns | 2022 |
| 36185208 | Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA. | Front Oncol | 2022 |
| 35247924 | A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors. | Clin Cancer Res | 2022 |
| 35110415 | Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer. | Clin Cancer Res | 2022 |
| 35168844 | Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial. | Eur Urol | 2022 |
| 35133686 | Alcohol dehydrogenase expression patterns in normal prostate, benign prostatic hyperplasia, and prostatic adenocarcinoma in African American and Caucasian men. | Prostate | 2022 |
| 34613570 | Phase Ia dose escalation study of OBP-801, a cyclic depsipeptide class I histone deacetylase inhibitor, in patients with advanced solid tumors. | Invest New Drugs | 2022 |
| 34624433 | Prostate cancer dormancy and recurrence. | Cancer Lett | 2022 |
| 33239713 | The biology and rationale of targeting nectin-4 in urothelial carcinoma. | Nat Rev Urol | 2021 |
| 37364021 | Development and pilot test of a physician-focused cancer clinical trials communication training intervention. | PEC Innov | 2021 |
| 33835826 | Tackling Diversity in Prostate Cancer Clinical Trials: A Report From the Diversity Working Group of the IRONMAN Registry. | JCO Glob Oncol | 2021 |
| 33916826 | Lysine 53 Acetylation of Cytochrome <i>c</i> in Prostate Cancer: Warburg Metabolism and Evasion of Apoptosis. | Cells | 2021 |
| 33496795 | Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial. | JAMA Netw Open | 2021 |
| 34738088 | Autophagy Inhibition by Targeting PIKfyve Potentiates Response to Immune Checkpoint Blockade in Prostate Cancer. | Nat Cancer | 2021 |
| 34562615 | Predicted Immunogenicity of CDK12 Biallelic Loss-of-Function Tumors Varies across Cancer Types. | J Mol Diagn | 2021 |
| 34535162 | DISCO App: study protocol for a randomized controlled trial to test the effectiveness of a patient intervention to reduce the financial burden of cancer in a diverse patient population. | Trials | 2021 |
| 34593448 | Symptom Outcomes of Cancer Patients With Clival Metastases Treated With Radiotherapy: A Study of 44 Patients. | Anticancer Res | 2021 |
| 33991512 | Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EVâ¿¿201): a multicentre, single-arm, phase 2 trial. | Lancet Oncol | 2021 |
| 34206543 | Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells. | Int J Mol Sci | 2021 |
| 33979195 | Evolution of Disparities in Prostate Cancer Treatment: Is This a New Normal? | Am Soc Clin Oncol Educ Book | 2021 |
| 34286163 | A Phase 1 study Combining Pexidartinib, Radiation Therapy, and Androgen Deprivation Therapy in Men With Intermediate- and High-Risk Prostate Cancer. | Adv Radiat Oncol | 2021 |
| 33951180 | A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer. | Cancer | 2021 |
| 34001952 | Discovery of primary prostate cancer biomarkers using cross cancer learning. | Sci Rep | 2021 |
| 33974855 | Metastatic urothelial carcinoma. | Cancer Cell | 2021 |
| 33465745 | Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type. | Transl Oncol | 2021 |
| 32220973 | An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer. | Mol Cancer Ther | 2020 |
| 31790330 | Unpacking Trial Offers and Low Accrual Rates: A Qualitative Analysis of Clinic Visits With Physicians and Patients Potentially Eligible for a Prostate Cancer Clinical Trial. | JCO Oncol Pract | 2020 |
| 32031899 | EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma. | J Clin Oncol | 2020 |
| 32013612 | eHealth Activity among African American and White Cancer Survivors: A New Application of Theory. | Health Commun | 2020 |
| 32069422 | Detecting TRA-1-60 in Cancer via a Novel Zr-89 Labeled ImmunoPET Imaging Agent. | Mol Pharm | 2020 |
| 32940630 | Willingness to Discuss Clinical Trials Among Black vs White Men With Prostate Cancer. | JAMA Oncol | 2020 |
| 32986533 | Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. | JCO Oncol Pract | 2020 |
| 32897830 | Exploring Spatial-Temporal Changes in <sup>18</sup>F-Sodium Fluoride PET/CT and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide. | J Clin Oncol | 2020 |
| 32694156 | A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer. | Clin Cancer Res | 2020 |
| 32503813 | Diversity of Enrollment in Prostate Cancer Clinical Trials: Current Status and Future Directions. | Cancer Epidemiol Biomarkers Prev | 2020 |
| 32111923 | Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. | Prostate Cancer Prostatic Dis | 2020 |